Phase II Study of Neoadjuvant Pegylated Liposomal Doxorubicin and Cyclophosphamide plus /- Trastuzumab Followed by Docetaxel in Locally Advanced Breast Cancer (LABC)

被引：0
|
作者：
Tuxen, M. K. [1 ]
Cold, S. [2 ]
Tange, U. B. [3 ]
Soendergaard, S. B. [4 ]
Nielsen, D. L. [1 ]
机构：
[1] Herlev Univ Hosp, Dept Oncol, DK-2730 Herlev, Denmark
[2] Odense Univ Hosp, Dept Oncol, DK-5000 Odense, Denmark
[3] Rigshosp, Dept Oncol, DK-2100 Copenhagen, Denmark
[4] Herlev Univ Hosp, Dept Nucl Med, DK-2730 Herlev, Denmark
来源：
EUROPEAN JOURNAL OF CANCER | 2012年 / 48卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S173 / S173
页数：1
相关论文
共 50 条
  • [1] Phase II study of neoadjuvant pegylated liposomal doxorubicin and cyclophosphamide ± trastuzumab followed by docetaxel in locally advanced breast cancer
    Tuxen, Malgorzata K.
    Cold, Soeren
    Tange, Ulla B.
    Balslev, Eva
    Nielsen, Dorte L.
    [J]. ACTA ONCOLOGICA, 2014, 53 (10) : 1440 - 1445
  • [2] Phase II trial of docetaxel plus doxorubicin and cyclophosphamide in locally advanced breast cancer (LABC).
    Puertolas, T
    Grandez, R
    de Lobera, AR
    Lao, J
    Herrero, A
    Trufero, JM
    Pazo, R
    Orduña, VA
    Cortes, AA
    Torres, AA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 89S - 89S
  • [3] Phase II Study of Neoadjuvant Gemcitabine, Pegylated Liposomal Doxorubicin, and Docetaxel in Locally Advanced Breast Cancer
    Grazia, Artioli
    Simone, Mocellin
    Lucia, Borgato
    Alessandro, Cappetta
    Fernando, Bozza
    Giorgio, Zavagno
    Stefania, Zovato
    Alberto, Marchet
    Davide, Pastorelli
    [J]. ANTICANCER RESEARCH, 2010, 30 (09) : 3817 - 3821
  • [4] Pegylated liposomal doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy in locally advanced breast cancer (registration number: ChiCTR1900023052)
    Ruoyang Li
    Fuguo Tian
    Yixin Qi
    Li Ma
    Tao Zhou
    Yuntao Li
    Tianli Hui
    Lina Zhang
    Shuo Wang
    Zhenchuan Song
    [J]. Scientific Reports, 9
  • [5] Pegylated liposomal doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy in locally advanced breast cancer (registration number: ChiCTR1900023052)
    Li, Ruoyang
    Tian, Fuguo
    Qi, Yixin
    Ma, Li
    Zhou, Tao
    Li, Yuntao
    Hui, Tianli
    Zhang, Lina
    Wang, Shuo
    Song, Zhenchuan
    [J]. SCIENTIFIC REPORTS, 2019, 9 (1)
  • [6] Phase II study of neoadjuvant gemcitabine (GC), pegylated liposomal doxorubicin (DX) and docetaxel (TT) in locally advanced breast cancer
    Cartei, G.
    Borgato, L.
    Lombardi, G.
    Cappetta, A.
    Bozza, F.
    Zovato, S.
    Zavagno, G.
    Mocellin, S.
    Artioli, G.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [7] A phase II study of docetaxel followed by vinorelbine and doxorubicin in the neoadjuvant treatment of locally advanced breast cancer
    Youssef, A. C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [8] Prospective phase II study of neoadjuvant doxorubicin followed by cisplatin/docetaxel in locally advanced breast cancer
    Al-Tweigeri, Taher A.
    Ajarim, Dahish S.
    Alsayed, Adher A.
    Rahal, Mohamed M.
    Alshabanah, Mohamed O.
    Tulbah, Asma M.
    Al-Malik, Osama A.
    Fatani, Doha M.
    El-Husseiny, Gamal A.
    Elkum, Naser B.
    Ezzat, Adnan A.
    [J]. MEDICAL ONCOLOGY, 2010, 27 (03) : 571 - 577
  • [9] Prospective phase II study of neoadjuvant doxorubicin followed by cisplatin/docetaxel in locally advanced breast cancer
    Taher A. Al-Tweigeri
    Dahish S. Ajarim
    Adher A. Alsayed
    Mohamed M. Rahal
    Mohamed O. Alshabanah
    Asma M. Tulbah
    Osama A. Al-Malik
    Doha M. Fatani
    Gamal A. El-Husseiny
    Naser B. Elkum
    Adnan A. Ezzat
    [J]. Medical Oncology, 2010, 27 : 571 - 577
  • [10] Phase II study of neoadjuvant docetaxel (T), doxorubicin (A) and capecitabine (X) in locally advanced or inflammatory breast cancer (LABC)
    Perez-Manga, G.
    Mendez, M.
    Palomero, M. I.
    Quiben, R.
    Belon, J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345